Enzyre closes Series A financing round of €12 million

Enzyre, which is developing breakthrough ambulant diagnostic technology for blood coagulation testing, has raised €12 million in a Series A financing led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment as technology partner and existing investors, Takeda Ventures and Novalis Biotech. Part of the funding is an Innovation Credit from the Dutch Government. The proceeds from the financing will enable Enzyre to further develop its unique diagnostic technology platform, EnzyPad, which will enable hemophilia patients to determine and monitor their coagulation status from home in real-time. Olym advised Enzyre in this funding round.

FlexiDAO closes series A funding round led by SET Ventures

FlexiDAO, a leading software provider for 24/7 electricity and carbon tracking, has secured a $6.5 million investment round led by SET Ventures, with investment from Google and the Microsoft Climate Innovation Fund, and existing investor EIT InnoEnergy. FlexiDAO enables companies and governments to operate on round-the-clock carbon-free energy, by certifying and tracing their electricity and its true carbon content, every hour of every day. We advised lead investor SET Ventures on this series A investment round.

Sale of M&I Broadcast Services to Valsoft Corporation

Valsoft Corporation Inc, a Canadian-based company specializing in the acquisition and development of software businesses, has acquired M&I Broadcast Services, a broadcast services software company that provides appealing, mission-critical software to the industry. M&I has several solutions across several broadcast platforms, including radio automation software OmniPlayer, as well as Nimbus Newsroom for radio, TV and online. M&I software is trusted by prominent European media companies such as RTL, DPG Media, Radio Italia and Talpa. We advised the selling shareholder on this transaction.

Thorizon raises €12.5 million for clean nuclear technology

We advised Thorizon on its 12.5 million euro funding round for the development of a new generation of nuclear power plants. The ‘Thorium molten salt reactor’ developed by Thorizon will use long-lived waste in combination with the abundant metal Thorium as fuel. This makes the reactor capable of making an important contribution to a safe, virtually inexhaustible and CO2-free energy supply. The investors are a strong team of private and public sector parties, including Positron Ventures, Invest-NL, Huisman, PDENH and Impuls Zeeland.

PSG invests in Rodeo Software

Rodeo Software is a leading cloud-native project management software provider with a focus on creative services companies. PSG is a leading growth equity firm that focuses on partnering with mid-market software and technology-enabled services companies. We advised Rodeo Software and its shareholders, including No Such Ventures, on the transaction with PSG.

ETPA raises €5M by SET Ventures and ABN AMRO

Energy Trading Platform Amsterdam B.V. (ETPA) has been awarded a license to operate as a pan-European intraday energy exchange. By making energy trading faster and cheaper, ETPA’s intraday trading platform contributes to a flexible energy system that can absorb more energy from renewable sources. With the license, the company can expand its reach and offer services to energy traders across Europe. To support its international growth ambitions, ETPA raised € 5 million in growth financing from energy transition expert SET Ventures and sustainable finance leader ABN AMRO Sustainable Impact Fund. We advised ETPA on this transaction.

Axion BioSystems acquires CytoSMART

Axion BioSystems is a US-based life sciences tools company focused on advanced live-cell assay systems and a portfolio company of Summa Equity. Axion BioSystems has acquired CytoSMART, a Dutch biotechnology company focused on kinetic live-cell imaging analysis. The acquisition of CytoSMART puts Axion in a position for significant expansion in the fields of stem cell research, immuno-oncology, cell-based therapies, and drug discovery. We advised CytoSMART and its selling shareholders, including Holland Capital, BOM and ECFG (Eindhoven Corporate Finance Group), on this transaction.

SET Ventures participates in a EUR 13 million round in Sensorfact

We advised SET Ventures in its investment, jointly with FORWARD.one and Korys, in the Utrecht-based climate scale-up Sensorfact. Sensorfact helps companies in the manufacturing industry to save up to 15% on energy bills with intelligent energy management and energy-saving advice.

Sale of Quantib to RadNet Inc.

We advised the former shareholders of Quantib, including Holland Capital, InnovationQuarter and Erasmus Medical Centre, in the sale of shares in Quantib to RadNet, Inc. (NASDAQ: RDNT), a US leader in providing high-quality diagnostic imaging services through a network of 350 owned and operated outpatient imaging centers. Quantib is a leading radiology artificial intelligence (“AI”) company focusing on clinical solutions for prostate cancer, breast cancer and neurodegeneration.

Standard Investment sells Synres to COIM

Standard Investment sold Synres (producer of synthetic resins for coatings/paints) to the Italian chemical group COIM. In 2015, Standard Investment together with management acquired Synres from DSM. In six years, volumes have grown by more than 60% and an extensive transformation program has been implemented. COIM is an international producer of speciality chemicals with head office in Milan, Italy. The acquisition is aimed on one hand at enhancing the existing production and expertise of Synres in the field of resins and, on the other hand, at creating added value for both shareholders and employees. Olym acted for Standard Investment in this transaction.